ENGLISH ABSTRACT
JOURNAL ARTICLE
REVIEW
Add like
Add dislike
Add to saved papers

[Diagnostic approach to the anemic cancer patient].

Tumori 1997 July
The anemia of the neoplastic patient can be: the first sign of a yet unknown neoplasia; a sign of progressive disease; an effect of therapy. The hemochromocytometric will define if the anemia is normocytic, microcytic or macrocytic. The reticulocyte counts will define the degree of marrow erythrocyte production. Thus specific algorithms could be used for trying to define the origin of the anemia. On the basis of the patient history, physical examination and other ad hoc exams it will be possible to determine the origin of the anemia keeping into mind the types of anemia of the neoplastic patients: anemia due to damage of the erythron as a consequence of chemotherapy; anemia of chronic disorders with a multiple pathogenesis. A decreased EPO production is often relevant; anemia due to renal damage (platinum compounds, anfotericin B) with decreased EPO production. A correct approach will allow the identification of the cause of the anemia and a correct treatment. Serum EPO determination can be useful to decide for EPO administration.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app